JP2013532651A - シロドシンと塩基性コポリマーとの混合物を含む経口投与用医薬品 - Google Patents

シロドシンと塩基性コポリマーとの混合物を含む経口投与用医薬品 Download PDF

Info

Publication number
JP2013532651A
JP2013532651A JP2013520157A JP2013520157A JP2013532651A JP 2013532651 A JP2013532651 A JP 2013532651A JP 2013520157 A JP2013520157 A JP 2013520157A JP 2013520157 A JP2013520157 A JP 2013520157A JP 2013532651 A JP2013532651 A JP 2013532651A
Authority
JP
Japan
Prior art keywords
silodosin
pharmaceutically acceptable
copolymer
pharmaceutical product
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013520157A
Other languages
English (en)
Japanese (ja)
Inventor
リムクス，カトリーン
ブルエック，サンドラ
Original Assignee
ラティオファルム ゲー・エム・ベー・ハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラティオファルム ゲー・エム・ベー・ハー filed Critical ラティオファルム ゲー・エム・ベー・ハー
Publication of JP2013532651A publication Critical patent/JP2013532651A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013520157A 2010-07-23 2011-07-21 シロドシンと塩基性コポリマーとの混合物を含む経口投与用医薬品 Withdrawn JP2013532651A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10170649 2010-07-23
EP10170649.7 2010-07-23
PCT/EP2011/062566 WO2012010669A2 (fr) 2010-07-23 2011-07-21 Médicament d'administration orale contenant un mélange de silodosine et d'un copolymère basique

Publications (1)

Publication Number Publication Date
JP2013532651A true JP2013532651A (ja) 2013-08-19

Family

ID=44628851

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013520157A Withdrawn JP2013532651A (ja) 2010-07-23 2011-07-21 シロドシンと塩基性コポリマーとの混合物を含む経口投与用医薬品

Country Status (3)

Country Link
EP (1) EP2595607A2 (fr)
JP (1) JP2013532651A (fr)
WO (1) WO2012010669A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016051782A1 (fr) * 2014-09-30 2016-04-07 キッセイ薬品工業株式会社 Préparation pour voie orale dans laquelle le goût amer d'un médicament au goût amer est masqué
JP2016138073A (ja) * 2015-01-29 2016-08-04 大原薬品工業株式会社 安定性を改善した、シロドシンを含有する錠剤
JP2017014119A (ja) * 2015-06-26 2017-01-19 東和薬品株式会社 経口医薬組成物
JP2018065752A (ja) * 2016-10-17 2018-04-26 東和薬品株式会社 シロドシン含有医薬組成物とその製造方法
JP2018199699A (ja) * 2013-03-26 2018-12-20 キッセイ薬品工業株式会社 シロドシンの苦味をマスキングした経口投与製剤
JP2019070045A (ja) * 2019-02-06 2019-05-09 大原薬品工業株式会社 安定性を改善した、シロドシンを含有する錠剤

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140243383A1 (en) * 2011-08-24 2014-08-28 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
WO2014006635A2 (fr) * 2012-07-02 2014-01-09 Hetero Research Foundation Compositions orales solides de silodosine
KR102206104B1 (ko) * 2014-04-03 2021-01-22 한미약품 주식회사 실로도신을 포함하는 과립물, 및 이를 포함하는 약학적 조성물 및 제형
EP3354283B1 (fr) 2017-06-20 2019-08-07 Alfred E. Tiefenbacher (GmbH & Co. KG) Composition de capsule pharmaceutique comprenant de la silodosine
CN112933084A (zh) * 2019-12-10 2021-06-11 广东东阳光药业有限公司 一种赛洛多辛组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0600675B1 (fr) 1992-12-02 1998-07-08 Kissei Pharmaceutical Co., Ltd. Composés indoliniques pour le traitement de la dysurien
DE19653605C2 (de) 1996-12-20 2002-11-28 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems
JP4324266B2 (ja) * 1999-02-26 2009-09-02 キッセイ薬品工業株式会社 α１Ａアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤
UA78854C2 (en) 2002-09-06 2007-04-25 Kissei Pharmaceutical Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same
JP4523265B2 (ja) 2002-11-13 2010-08-11 旭化成ファーマ株式会社 排尿障害治療用口腔内崩壊製剤
UA84694C2 (ru) 2002-12-16 2008-11-25 Киссеи Фармасьютикал Ко., Лтд. Капсула для лечения дизурии, содержащая гранулиновое индолиновое соединение - блокатор -адренорецепторов
US20060013880A1 (en) 2004-07-19 2006-01-19 Robert Femia Formulation stabilizer for proton pump inhibitors

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018199699A (ja) * 2013-03-26 2018-12-20 キッセイ薬品工業株式会社 シロドシンの苦味をマスキングした経口投与製剤
WO2016051782A1 (fr) * 2014-09-30 2016-04-07 キッセイ薬品工業株式会社 Préparation pour voie orale dans laquelle le goût amer d'un médicament au goût amer est masqué
JPWO2016051782A1 (ja) * 2014-09-30 2017-07-13 キッセイ薬品工業株式会社 苦味を有する薬剤の苦味をマスキングした経口投与製剤
JP2016138073A (ja) * 2015-01-29 2016-08-04 大原薬品工業株式会社 安定性を改善した、シロドシンを含有する錠剤
JP2017014119A (ja) * 2015-06-26 2017-01-19 東和薬品株式会社 経口医薬組成物
JP2018065752A (ja) * 2016-10-17 2018-04-26 東和薬品株式会社 シロドシン含有医薬組成物とその製造方法
JP7023600B2 (ja) 2016-10-17 2022-02-22 東和薬品株式会社 シロドシン含有医薬組成物とその製造方法
JP2019070045A (ja) * 2019-02-06 2019-05-09 大原薬品工業株式会社 安定性を改善した、シロドシンを含有する錠剤

Also Published As

Publication number Publication date
WO2012010669A2 (fr) 2012-01-26
EP2595607A2 (fr) 2013-05-29
WO2012010669A3 (fr) 2012-07-26

Similar Documents

Publication Publication Date Title
JP2013532651A (ja) シロドシンと塩基性コポリマーとの混合物を含む経口投与用医薬品
RU2404775C2 (ru) Фармацевтические композиции, содержащие иматиниб и замедлитель высвобождения
TWI478712B (zh) 釋控性醫藥組成物
TW201904565A (zh) 控釋藥物組合物及其製備方法
JP2005517690A (ja) 固体薬物分散物を含有する即時放出剤形
CA2729979A1 (fr) Compositions pharmaceutiques comprenant du 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide
CN106232144B (zh) 固体分散体
TW200848056A (en) Solid dispersion of a neurokinin antagonist
JP5714562B2 (ja) 経口用徐放性固形製剤
JP2010519200A (ja) シロスタゾールを含む制御放出製剤及びその製造方法
JP2023513444A (ja) ダサチニブの非晶質固体分散体及びその使用
US20140319720A1 (en) Pharmaceutical compositions comprising rivaroxaban
JP2016117738A (ja) シロドシン−シクロデキストリン包接化合物
EP2701689B1 (fr) Compositions pharmaceutiques de raltégravir, procédés de préparation et utilisation de celles-ci
JPWO2008114859A1 (ja) ピラゾール誘導体を含有する医薬組成物
TW201609195A (zh) 固體抗病毒劑型
JP6680297B2 (ja) 経口投与用医薬組成物
CA2934586A1 (fr) Composition pharmaceutique
US20230147712A1 (en) Oleyl phosphocholine containing granulates
JP5669751B2 (ja) 低い経口生物学的利用能を有する化合物のプレ圧縮崩壊性製剤
JP2022113667A (ja) エドキサバン含有医薬組成物
WO2019004980A2 (fr) Compositions pharmaceutiques orales solides d'étéxilate de dabigatran
WO2022177983A1 (fr) Compositions pharmaceutiques de cabozantinib
EP4279075A1 (fr) Composition pharmaceutique contenant de l'elagolix
RU2696870C2 (ru) Пероральный препарат с замедленным высвобождением

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130517

A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20141007